Wolters Kluwer

TECHNICAL BULLETIN

Valuable information regarding Medi-Span® applications

AT A GLANCE

Audience

Developers and end-users of MDDB, Canadian MDDB, Canadian Drug File v2, DIB, Middleware, The Medi-Span Solution, Medi-Span Price Rx, MED-File, MED-File v2, SDDB, Medi-Span Clinical API, Medi-Span Clinical Via Web Services, and Global Drug Database

Abstract

Planned GPI changes to the GPI/TCS, IV Potassium Update: Australia and UK Replace mEq with mmol, "Injectable" Dosage Form, Transitioning from "Hyaluronate" to "Hyaluronic Acid", Glucagon Products No Longer Differentiated by Manufacturing Method

System Impact

Yes

Customer Support

medispan-support@wolterskluwer.com

Announcing GPI/TCS Changes

Purpose

The purpose of this technical bulletin is to provide details regarding planned changes to our Generic Product Identifiers (GPIs) and Therapeutic Classification System (TCS).

This technical bulletin is for developers and end-users of Master Drug Data Base (MDDB), Canadian Master Drug Data Base (Canadian MDDB), Canadian Drug File v2, The Drug Information Bridge (DIB), Medi-Span Price Rx, Medi-Span Electronic Drug File (MED-File), Medi-Span Electronic Drug File v2 (MED-File v2), Standard Drug Data Base (SDDB), Medi-Span Clinical API, Medi-Span Clinical Web Services, and Global Drug Database.

Note: The changes to the GPIs and TCS noted in this bulletin are effective on or after the **September 22, 2025** daily drug file releases. Weekly, monthly, semi-monthly, and quarterly customers will see these revisions with their **October 1, 2025** releases. A listing of all the GPI changes (see the *GPI Changes* section on page 4) and an explanation of the optionally available electronic file layout (see the *Electronic File of GPI Changes* section on page 10) are provided in this bulletin.

Abstract

Please note the following important information concerning the GPI changes:

- **The GPI and TCS will have planned changes effective on or after the September 22, 2025 daily drug file or Medi-Span Price Rx releases.**
- **In response to national safety mandates, Medi-Span is planning a GPI split to create new entries that reflect potassium strength in mmol for Australia and the UK.**
- **The dosage form of "injectable" is somewhat vague. We researched several GPIs with this dosage form and split products to GPIs with more specific dosage forms such as "solution" or "suspension".**
- **A terminology update is underway to standardize all "Cross-Linked Hyaluronate" product classifications under the preferred term "Cross-Linked Hyaluronic Acid," improving consistency and reducing redundancy in the GPI system.**
- **We are merging all glucagon products into a single classification, removing the distinction between recombinant (rDNA) and synthetic forms. This change reflects evolving manufacturing practices, where some products have shifted to synthetic production without updating their NDCs.**

System Impact

Review these changes to determine what impact, if any, they may have on your application(s).

Planned GPI Changes

With the upcoming GPI changes, a number of NDC/UPC/HRIs or other drug product identifiers will be linked to newly created GPI and/or different existing GPI values.

The improved categorization of these drug products is anticipated to provide a positive impact if your applications include drug formulary and therapeutic alternative applications.

Generally, a GPI does not change for an NDC/UPC/HRI or any other drug product identifier. However, if the TCS is altered, it may be reassigned to help maintain the integrity and usefulness of the system, or it may also be reassigned if a dosage form or strength designation for an ingredient needs refinement. Lastly, it may change if there is a correction to the original GPI assignment.

Users who subscribe to offerings that are updated daily will begin to see these revisions on or after **September 22, 2025**. Weekly, monthly, semi-monthly, and quarterly customers will see these revisions with their **October 1, 2025** releases.

Medi-Span Price Rx users who include the GPI in subset definitions must reevaluate subset definitions that might potentially be affected by information displayed in the GPI Planned Changes Report (available by Alerts). Subsets may need to be changed when the new GPI data is linked to NDC/UPC/HRIs on or after **September 22, 2025.**

A new Electronic File of GPI changes that are contained in this technical bulletin is available via the Medi-Span website, at https://wds.medispan.com. Login with your username and password, select the "Documentation" option, then select "General Documentation," and finally select the "Drug File Reports" folder. If you have not already obtained access to the website, please contact Customer Support to register and obtain a Web Delivery login username and password.

Note: Some updates to GPIs that affect clinical information will continue to be made without advanced notice. For U.S. and Canada, these changes are published in weekly versions of *DataFacts*.

Note For US Customers: Not every GPI change will impact the US marketplace. For changes listed as "splits" (COMPLETE REPLACE CODE = "N"), we encourage you to use the "NDCs affected by GPI Changes" Excel file, which will be available on the Medi-Span website by the end of July 2025 and announced in *DataFacts*. This file will indicate which NDC/UPC/HRIs (if any) will be affected by the GPI Change Plan.

The file will also be updated once in the week prior to the implementation of the GPI Change Plan to account for new NDCs entering the marketplace. Any applicable US NDC/UPC/HRIs added after the report is generated will not be included. In this report, US NDC/UPC/HRIs with GPIs that are "split" are only included if their GPI will change.

IV Potassium Update: Australia and UK Replace mEq with mmol

In response to national safety mandates, Medi-Span is planning a GPI split to create new entries that reflect potassium chloride strength in millimoles (mmol) for Australia and the United Kingdom. This change is driven by national guidelines, where intravenous (IV) potassium is prescribed and labeled in mmol rather than milliequivalents (mEq).

By aligning with these national guidelines, Medi-Span aims to support safer clinical workflows and help reduce the risk of medication errors. The planned GPI split will help ensure that healthcare providers in these regions have access to drug data that reflects local regulatory expectations.

Importantly, this change will be limited to Australia and the UK. All other countries will continue to see potassium chloride strength represented in mEq, and no changes will be made to their existing drug file configurations. This targeted approach supports compliance with local mandates while minimizing disruption to global users.

This initiative highlights the critical role of drug information systems in promoting medication safety and underscores the importance of adapting global databases to meet regional healthcare standards.

"Injectable" Dosage Form

The term "Injectable" as a dosage form in our system is unspecific. It is more appropriately used as a route in combination with a specific dosage form, such as "solution" or "suspension." To address this, we researched GPIs with the "Injectable" designation and reclassified products into GPIs with more specific dosage forms.

Transitioning from "Hyaluronate" to "Hyaluronic Acid"

To improve consistency across product classifications, a terminology update is underway to standardize all "Cross-Linked Hyaluronate" entries under the preferred term "Cross-Linked Hyaluronic Acid." This change follows a review of overlapping entries and aims to eliminate redundancy while aligning with scientific naming conventions.

The update includes renaming and merging various product types, including gels and lidocaine combinations. A two-phase rollout is planned: renaming and merging in September 2025, followed by additional research in March 2026 to identify any sodium salt variants that may require separate classification. This initiative supports a cleaner, more reliable product database.

Glucagon Products No Longer Differentiated by Manufacturing Method

We are updating our database to merge all glucagon products - whether produced via recombinant DNA (rDNA) technology or synthetic peptide synthesis - under a single classification. This means we will no longer distinguish between "Glucagon (rDNA)" and "Glucagon" in our GPI structure.

This change reflects a shift in manufacturing practices: some manufacturers have transitioned from rDNA to synthetic methods without changing their NDCs. Maintaining a separate classification for rDNA is no longer accurate or clinically meaningful.

By consolidating these entries, we ensure our data remains aligned with current labeling and manufacturing trends, while simplifying product identification and substitution processes.

GPI Changes

The following table lists the planned changes to GPI and Therapeutic Classes. A description of each column name is provided after the table in the *File Layout Descriptions* section.

The column **OLD GPI USED IN U.S.** reflects 14-character OLD GPI values that are used in U.S. products when the products are either active or 48-months inactive from the time that this table was created

(07/01/2025). If an OLD GPI Used in U.S. has a Yes denoted, then that OLD GPI value is currently being used in a U.S. product. Please note that this does not always imply that a U.S. product will be moving from the OLD to the NEW GPI in the case of GPI splits. This attribute is specific to Record Code Values of '5' (Full GPI).

The column NEW GPI may include a GPI that already exists in the database but is a new GPI for a specific product. The GPI represented in the NEW GPI column may or may not be used for a U.S. product.

Additionally, an Excel spreadsheet of the active and 48-months inactive U.S. NDC/UPC/HRIs on file currently affected by these changes is anticipated to be available via the Medi-Span website at https://wds.medispan.com by the end of July 2025 and will be announced in *DataFacts*. Any applicable U.S. NDC/UPC/HRIs added to the files after the report is generated in July will not be included in this table. The spreadsheet will include the U.S. NDC/UPC/HRIs, drug name, current GPI, and the projected new GPI as of **September 22, 2025**.

In this report, U.S. NDC/UPC/HRIs having GPIs that are "split" (for example, some NDC/UPC/HRIs under the GPI may go to one or more new GPIs while other NDC/UPC/HRIs remain the same as before the split) are only included in the report if their GPI has changed. Contact Customer Support at medispan-support@wolterskluwer.com for access to the Medi-Span website.

Note: All GPIs affected by these changes are reported in the Old GPI column below. **Your current file may not contain all GPIs found in this field.** Some GPIs listed may be associated with products NOT found in the U.S. or with products that have become inactive more than 24 to 48 months.

GPI Changes Effective September 22, 2025

OLD GPI	OLD REC CD	NEW GPI	NEW REC CD	COMPLETE REPLACE CODE	REASON CODE	NEW GPI NAME	OLD GPI USED IN US†
04000020150120	5	04000020100110	5	N	A	Doxycycline Hyclate Cap 100 MG	
04000020150310	5	04000020000305	5	N	A	Doxycycline Monohydrate Tab 50 MG	
04000020150310	5	04000020100305	5	N	A	Doxycycline Hyclate Tab 50 MG	
04000020150320	5	04000020000310	5	N	A	Doxycycline Monohydrate Tab 100 MG	
04000020150320	5	04000020100310	5	N	A	Doxycycline Hyclate Tab 100 MG	
04000020156720	5	04000020106710	5	N	A	Doxycycline Hyclate Cap DR Particles 50 MG	
04000020156730	5	04000020106720	5	N	A	Doxycycline Hyclate Cap DR Particles 100 MG	
17100008001840	5	1710000800E680	5	N	B	Hepatitis A Vaccine Susp Prefilled Syr 1440 EL Unit/ML	Yes
17100008001860	5	1710000800E602	5	N	B	Hepatitis A Vaccine Susp Prefilled Syr 25 Unit/0.5ML	Yes
17100008001870	5	1710000800E605	5	N	B	Hepatitis A Vaccine Susp Prefilled Syr 50 Unit/ML	Yes
17100008001970	5	1710000800E640	5	A	B	Hepatitis A Vaccine Susp Prefilled Syringe 160 Unit/0.5ML	
171000500022	7	171000500018	7	A	B	Poliovirus Vaccine, IPV Suspension	
17100050002200	5	17100050001800	5	A	B	Poliovirus Vaccine, IPV Inj Susp	
17100050002250	5	17100050001800	5	A	B	Poliovirus Vaccine, IPV Inj Susp	Yes
17100090002200	5	17100090001900	5	N	B	Yellow Fever Vaccine For Inj Suspension	Yes
17100090002200	5	17100090001910	5	N	B	Yellow Fever Vaccine For Subcutaneous Suspension	Yes
18990002202210	5	18990002201808	5	Y	B	Tetanus-Diphtheria Toxoids (Td) Inj 5-2 LF/0.5ML	Yes
18990003221815	5	1899000322E615	5	N	B	Tet-Diph-Acell Pertuss Ad Pref Syr 5-2-15.5 LF-MCG/0.5ML	Yes
18990003221820	5	1899000322E620	5	N	B	Tet-Diph-Acell Pertuss Ad Pref Syr 5-2.5-18.5 LF-MCG/0.5ML	Yes
19100020002200	5	19100020002000	5	N	B	Immune Globulin (Human) IM Soln	Yes
19100020002200	5	19100020002010	5	N	B	Immune Globulin (Human) IM Soln 160 MG/ML	Yes
19100020002200	5	19100020002020	5	N	B	Immune Globulin (Human) IM Soln 320 MG/2ML	Yes
19100020002200	5	19100020002022	5	N	B	Immune Globulin (Human) IM Soln 330 MG/2ML	Yes
19100020002200	5	19100020002040	5	N	B	Immune Globulin (Human) IM Soln 800 MG/5ML	Yes
19100020002200	5	19100020002070	5	N	B	Immune Globulin (Human) IM Soln 1650	Yes

OLD GPI	OLD REC CD	NEW GPI	NEW REC CD	COMPLETE REPLACE CODE	REASON CODE	NEW GPI NAME	OLD GPI USED IN US†
						MG/10ML	
215500402022	7	215500402018	7	Y	B	Irinotecan HCl Liposome Suspension	
21550040202220	5	21550040201820	5	Y	B	Irinotecan HCl Liposome IV Susp 43 MG/10ML (4.3 MG/ML)	Yes
2199000205	4	2199000205	4	C	D	Atezolizumab-Hyaluronidase-tqjs	
219900020520	7	219900020520	7	C	D	Atezolizumab-Hyaluronidase-tqjs Solution	
21990002052021	5	21990002052021	5	C	D	Atezolizumab (w/ Hyaluronidase) Inj Soln 1875 MG/15ML	
2199000210	4	2199000215	4	Y	A	Daratumumab-Hyaluronidase-fihj	
219900021020	7	219900021520	7	Y	A	Daratumumab-Hyaluronidase-fihj Solution	
21990002102020	5	21990002152021	5	Y	A	Daratumumab (w/ Hyaluronidase) Inj Soln 1800 MG/15ML	
21990002642070	5	21990002642070	5	C	D	Rituximab (w/Hyaluronidase) Subcutaneous Soln 1400 MG/11.7ML	
21990002642080	5	21990002642080	5	C	D	Rituximab (w/Hyaluronidase) Subcutaneous Soln 1600 MG/13.4ML	
2199000271	4	2199000272	4	Y	A	Trastuzumab-Hyaluronidase-oysk	
219900027120	7	219900027220	7	Y	A	Trastuzumab-Hyaluronidase-oysk Solution	
21990002712020	5	21990002722021	5	Y	A	Trastuzumab (w/ Hyaluronidase) Inj Soln 600 MG/5ML	
2199000350	4	2199000355	4	Y	A	Pertuzumab-Trastuzumab-Hyaluronidase-zzxf	
219900035020	7	219900035520	7	Y	A	Pertuzumab-Trastuzumab-Hyaluronidase-zzxf Solution	
21990003502020	5	21990003552021	5	Y	A	Pertuzumab-Trastuzumab (w/ Hyaluronidase) Inj 60-60 MG/ML	
21990003502040	5	21990003552031	5	Y	A	Pertuzumab-Trastuzumab (w/ Hyaluronidase) Inj 80-40 MG/ML	
22100020202010	5	22100020202011	5	N	B	Dexamethasone Sod Phosphate Preservative Free Inj 10 MG/ML	Yes
2730001010	4	2730001000	4	A	A	Glucagon	
273000101021	7	273000100021	7	A	A	Glucagon Reconstituted Solution	
27300010102110	5	27300010002105	5	A	A	Glucagon For Inj 1 MG	
273000101064	7	273000100021	7	A	A	Glucagon Reconstituted Solution	
27300010106410	5	27300010002105	5	A	A	Glucagon For Inj 1 MG	Yes
2730001015	4	2730001020	4	A	A	Glucagon HCl	
273000101521	7	273000102021	7	A	A	Glucagon HCl Reconstituted Solution	
27300010152110	5	27300010202105	5	A	A	Glucagon HCl For Inj 1 MG	Yes
30902545102020	5	30902545102021	5	Y	B	Eladocagene Exuparvovec-tneq Inj Soln 280000000000 VG/0.5ML	
3520002010E530	5	3520002010E532	5	N	B	Lidocaine HCl(Cardiac) IV PF Soln Pref Syr 100 MG/5ML (2%)	Yes
41400020101210	5	41400020102060	5	A	B	Promethazine HCl Oral Soln 6.25 MG/5ML	Yes
4250990260	4	4250990261	4	Y	A	Polyethylene Glycol-Propylene Glycol	
425099026020	7	425099026120	7	Y	A	Polyethylene Glycol-Propylene Glycol Solution	
42509902602010	5	42509902612010	5	Y	A	Polyethylene Glycol-Propylene Glycol Nasal Soln 15-5%	
42509902602020	5	42509902612020	5	Y	A	Polyethylene Glycol-Propylene Glycol Nasal Soln 15-20%	
42509902602030	5	42509902612030	5	Y	A	Polyethylene Glycol-Propylene Glycol Nasal Soln 16-5%	
425099026040	7	425099026140	7	Y	A	Polyethylene Glycol-Propylene Glycol Gel	
42509902604020	5	42509902614020	5	Y	A	Polyethylene Glycol-Propylene Glycol Nasal Gel 15-20%	
44100080080120	5	44100080080124	5	N	B	Tiotropium Bromide Inhal Cap 13 MCG (Base Equiv)	
4410008010	4	4410008008	4	Y	A	Tiotropium Bromide	
441000801001	7	441000800801	7	Y	A	Tiotropium Bromide Capsule	
44100080100120	5	44100080080130	5	Y	A	Tiotropium Bromide Inhal Cap 18 MCG (Base Equiv)	Yes
441000801034	7	441000800834	7	Y	A	Tiotropium Bromide Aerosol Solution	
44100080103410	5	44100080083410	5	Y	A	Tiotropium Bromide Inhal Aerosol 1.25 MCG/ACT	Yes
44100080103420	5	44100080083420	5	Y	A	Tiotropium Bromide Inhal Aerosol 2.5 MCG/ACT	Yes
44100080103450	5	44100080083450	5	Y	A	Tiotropium Bromide Inhal Aerosol 9 MCG/ACT	
4630003100	6	4630003000	6	A	A	Psyllium	
4630003110	4	4630003010	4	A	A	Psyllium	
463000311001	7	463000301001	7	A	A	Psyllium Capsule	
46300031100120	5	46300030100112	5	A	A	Psyllium Cap 350 MG	
46300031100140	5	46300030100128	5	A	A	Psyllium Cap 470 MG	
463000311030	7	463000301030	7	A	A	Psyllium Packet	
46300031103017	5	46300030103005	5	A	A	Psyllium Packet 3.25 GM	
46300031103020	5	46300030103008	5	A	A	Psyllium Packet 3.5 GM	
46300031103025	5	46300030103012	5	A	A	Psyllium Packet 4 GM	
463000311077	7	463000301077	7	A	A	Psyllium Granules Effervescent	
46300031107720	5	46300030107720	5	A	A	Psyllium Effer Granules 3.5 GM/5.48GM	
4630003200	6	4630003000	6	A	A	Psyllium	

OLD GPI	OLD REC CD	NEW GPI	NEW REC CD	COMPLETE REPLACE CODE	REASON CODE	NEW GPI NAME	OLD GPI USED IN US†
4630003200	4	4630003010	4	A	A	Psyllium	
463000320029	7	463000301029	7	A	A	Psyllium Powder	
46300032002900	5	46300030102901	5	A	A	*Psyllium Powder**	
463000320030	7	463000301030	7	A	A	Psyllium Packet	
46300032003000	5	46300030103001	5	A	A	*Psyllium Packet**	
46600033002910	5	46600033003010	5	N	B	Polyethylene Glycol 3350 Oral Packet 8.5 GM	Yes
52100010000305	5	52700021000320	5	N	A	Chenodiol (BASDs) Tab 250 MG	Yes
52500030007530	5	52500030000670	5	A	B	Mesalamine Tab Delayed Release 1.2 GM	
525800501020	7	5258005010E5	7	N	B	Methylnaltrexone Bromide Solution Prefilled Syringe	
52580050102015	5	5258005010E515	5	N	B	Methylnaltrexone Bromide Soln Pref Syr 8 MG/0.4ML	Yes
52580050102020	5	5258005010E520	5	N	B	Methylnaltrexone Bromide Soln Pref Syr 12 MG/0.6ML	Yes
55350020003705	5	55350020003705	5	C	D	Estradiol Vaginal Cream 0.01%	Yes
6125380000	3	3090840000	3	Y	A	*Melanocortin 4 (MC4) Receptor Agonists***	
6125386000	6	3090846000	6	Y	A	Setmelanotide	
6125386000	4	3090846000	4	Y	A	Setmelanotide	
612538600020	7	309084600020	7	Y	A	Setmelanotide Solution	
61253860002020	5	30908460002020	5	Y	A	Setmelanotide Subcutaneous Soln 10 MG/ML	
6125386010	4	3090846010	4	Y	A	Setmelanotide Acetate	
612538601020	7	309084601020	7	Y	A	Setmelanotide Acetate Solution	
61253860102020	5	30908460102020	5	Y	A	Setmelanotide Acetate Subcutaneous Soln 10 MG/ML	Yes
6240990250	4	6240990260	4	Y	A	Ocrelizumab-Hyaluronidase-ocsq	
624099025020	7	624099026020	7	Y	A	Ocrelizumab-Hyaluronidase-ocsq Solution	
62409902502040	5	62409902602041	5	Y	A	Ocrelizumab (w/ Hyaluronidase) Inj Soln 920 MG/23ML	
64200010001015	5	64200010000912	5	N	B	Acetaminophen Liquid 160 MG/5ML	Yes
7580002000	6	7580002000	6	C	D	Cross-Linked Hyaluronic Acid	
7580002000	4	7580002000	4	C	D	Cross-Linked Hyaluronic Acid	
758000200040	7	758000200040	7	C	D	Cross-Linked Hyaluronic Acid Gel	
7580002000E4	7	7580002000E4	7	C	D	Cross-Linked Hyaluronic Acid Prefilled Syringe	
7580002000E420	5	7580002000E420	5	C	D	Cross-Linked Hyaluronic Acid Gel Prefilled Syringe 30 MG/3ML	Yes
7580002000E430	5	7580002000E430	5	C	D	Cross-Linked Hyaluronic Acid Gel Prefilled Syringe 40 MG/2ML	
7580002000E440	5	7580002000E440	5	C	D	Cross-Linked Hyaluronic Acid Gel Prefilled Syringe 60 MG/3ML	
7580002000E470	5	7580002000E470	5	C	D	Cross-Linked Hyaluronic Acid Gel Prefilled Syringe 90 MG/3ML	
78310000000100	5	82992007160125	5	N	A	*Fe Gluc-C-FA-B12-Manganese-Copper-Sorbitol Cap 250-1 MG***	Yes
78512000000320	5	78512046000315	5	N	A	*Prenat Vit w/Fe Bisglyc Chelate-FA Tab 20-1MG (1.7MG DFE)**	Yes
79100007000325	5	79100007000350	5	N	B	Calcium Carbonate Tab 1500 MG (600 MG Elemental Ca)	Yes
79700010002050	5	79700010002051	5	N	B	Potassium Acetate Inj 5 MMOL/ML	
79700030002001	5	79700030002007	5	N	B	Potassium Chloride Inj 1 MMOL/ML	
79700030002005	5	79700030002006	5	N	B	Potassium Chloride Inj 2 MMOL/ML	Yes
79700030002014	5	79700030002015	5	N	B	Potassium Chloride Inj 2.68 MMOL/ML	
79700030002070	5	79700030002071	5	N	B	Potassium Chloride Inj 20 MMOL/50ML	Yes
79700030002075	5	79700030002076	5	N	B	Potassium Chloride Inj 40 MMOL/100ML	Yes
79700030002078	5	79700030002079	5	N	B	Potassium Chloride Inj 13.4 MMOL/4ML	
79700030002082	5	79700030002083	5	N	B	Potassium Chloride Inj 13.4 MMOL/10ML	
79700030100430	5	79700030000430	5	N	A	Potassium Chloride Tab ER 10 mEq	Yes
79992002102020	5	79992002102019	5	N	B	KCl 20 MMOL/L (0.15%) in NaCl 0.9% Inj	Yes
79992002102025	5	79992002102026	5	N	B	KCl 30 MMOL/L (0.224%) in NaCl 0.9% Inj	
79992002102030	5	79992002102029	5	N	B	KCl 40 MMOL/L (0.3%) in NaCl 0.9% Inj	Yes
79993002102020	5	79993002102021	5	N	B	Potassium Chloride 20 MMOL/L (0.15%) in Dextrose 5% Inj	Yes
79993002102025	5	79993002102026	5	N	B	Potassium Chloride 30 MMOL/L (0.224%) in Dextrose 5% Inj	
79993002102030	5	79993002102031	5	N	B	Potassium Chloride 40 MMOL/L (0.3%) in Dextrose 5% Inj	
79993002102060	5	79993002102061	5	N	B	Potassium Chloride 20 MMOL/L (0.15%) in Dextrose 10% Inj	
79993003102017	5	79993003102001	5	N	B	KCl 20 MMOL/L (0.15%) in Dextrose 2.5% & NaCl 0.45% Inj	
79993003102019	5	79993003102002	5	N	B	KCl 20 MMOL/L (0.15%) in Dextrose 4% & NaCl 0.18% Inj	
79993003102024	5	79993003102003	5	N	B	KCl 20 MMOL/L (0.15%) in Dextrose 3.75% & NaCl 0.225% Inj	
79993003102025	5	79993003102004	5	N	B	KCl 20 MMOL/L (0.15%) in Dextrose 5% & NaCl 0.45% Inj	Yes
79993003102027	5	79993003102005	5	N	B	KCl 20 MMOL/L (0.15%) in Dextrose 5% & NaCl 0.9% Inj	Yes

OLD GPI	OLD REC CD	NEW GPI	NEW REC CD	COMPLETE REPLACE CODE	REASON CODE	NEW GPI NAME	OLD GPI USED IN US†
79993003102029	5	79993003102031	5	N	B	KCl 30 MMOL/L (0.224%) in Dextrose 4% & NaCl 0.18% Inj	
79993003102075	5	79993003102074	5	N	B	KCl 40 MMOL/L (0.3%) in Dextrose 4% & NaCl 0.18% Inj	
8240157000F820	5	8240157000E525	5	N	B	Pegfilgrastim Soln Prefill Syr/Infusion Dev 6 MG/0.6ML	Yes
82992007160120	5	82992007160125	5	N	B	*Fe Gluc-C-FA-B12-Manganese-Copper-Sorbitol Cap 250-1 MG***	
85805050002020	5	85805050012020	5	N	A	Eculizumab-aeeb IV Soln 300 MG/30ML (10 MG/ML)(For Infusion)	Yes
85805050002020	5	85805050022020	5	N	A	Eculizumab-aagh IV Soln 300 MG/30ML (10 MG/ML)(For Infusion)	Yes
86201000002000	5	86807018002025	5	N	A	Perfluorohexyloctane Ophth Soln 100%	Yes
86409902122045	5	86409902122046	5	N	B	Naphazoline w/ Antazoline Ophth-Nasal Soln 0.025-0.5%	
86655060002028	5	86655060002020	5	N	B	Ranibizumab Intravitreal Inj 0.5 MG/0.05ML (10 MG/ML)	
86655060002028	5	86655060302020	5	N	A	Ranibizumab-eqrn Intravitreal Inj 0.5 MG/0.05ML (10 MG/ML)	
86655060002030	5	86655060002020	5	A	B	Ranibizumab Intravitreal Inj 0.5 MG/0.05ML (10 MG/ML)	
8665506000E540	5	8665506000E520	5	A	B	Ranibizumab Intravitreal Soln Pref Syr 0.5 MG/0.05ML	
9025054200D520	5	9025054200D225	5	N	B	Guselkumab Soln Pen-injector 100 MG/ML	Yes
90850060003240	5	90850060103403	5	N	A	Lidocaine HCl Aerosol Soln 4%	Yes
9088802000	6	9088803000	6	A	A	Cross-Linked Hyaluronic Acid	
9088802010	4	9088803000	4	A	A	Cross-Linked Hyaluronic Acid	
9088802010E4	7	9088803000E4	7	A	A	Cross-Linked Hyaluronic Acid Prefilled Syringe	
9088802010E420	5	9088803000E418	5	A	A	Cross-Linked Hyaluronic Acid Gel Prefilled Syringe 18 MG/ML	
9088802010E425	5	9088803000E423	5	A	A	Cross-Linked Hyaluronic Acid Gel Prefilled Syringe 23 MG/ML	
9088802020	4	9088803020	4	A	A	Cross-Linked Hyaluronic Acid-Lidocaine	
908880202040	7	908880302040	7	A	A	Cross-Linked Hyaluronic Acid-Lidocaine Gel	
90888020204020	5	90888030204017	5	A	A	Cross-Linked Hyaluronic Acid w/ Lido 0.3% Inj Gel 22.5 MG/ML	
90888020204030	5	90888030204026	5	A	A	Cross-Linked Hyaluronic Acid w/ Lido 0.3% Inj Gel 26 MG/ML	
9089004540	4	7440002015	4	Y	A	DaxibotulinumtoxinA-lanm	
908900454021	7	744000201521	7	Y	A	DaxibotulinumtoxinA-lanm Reconstituted Solution	
90890045402120	5	74400020152120	5	Y	A	DaxibotulinumtoxinA-lanm For Inj 50 Unit	
90890045402140	5	74400020152140	5	Y	A	DaxibotulinumtoxinA-lanm For Inj 100 Unit	Yes
909480091022	7	909480091009	7	Y	B	Amniotic Fluid Allograft (Human) Liquid	
90948009102210	5	90948009100910	5	Y	B	*Amniotic Fluid Allograft (Human) Inj 0.25 ML***	Yes
90948009102220	5	90948009100920	5	Y	B	*Amniotic Fluid Allograft (Human) Inj 0.5 ML***	Yes
90948009102230	5	90948009100930	5	Y	B	*Amniotic Fluid Allograft (Human) Inj 1 ML***	Yes
90948009102240	5	90948009100940	5	Y	B	*Amniotic Fluid Allograft (Human) Inj 2 ML***	Yes
909480111022	7	909480111009	7	Y	B	Amniotic Membrane-Amniotic Fluid Allograft Liquid	
90948011102210	5	90948011100910	5	Y	B	*Amniotic Membrane-Amniotic Fluid Allograft Inj 0.25 ML***	Yes
90948011102220	5	90948011100920	5	Y	B	*Amniotic Membrane-Amniotic Fluid Allograft Inj 0.5 ML***	Yes
90948011102230	5	90948011100930	5	Y	B	*Amniotic Membrane-Amniotic Fluid Allograft Inj 1 ML***	Yes
90948011102240	5	90948011100940	5	Y	B	*Amniotic Membrane-Amniotic Fluid Allograft Inj 2 ML***	Yes
90948011102243	5	90948011100943	5	Y	B	*Amniotic Membrane-Amniotic Fluid Allograft Inj 2.5 ML***	Yes
90948011102250	5	90948011100950	5	Y	B	*Amniotic Membrane-Amniotic Fluid Allograft Inj 4 ML***	Yes
909480150022	7	909480150063	7	Y	B	Bone Tissue Allograft Miscellaneous	
90948015002215	5	90948015006315	5	Y	B	*Bone Tissue Allograft (Human) Inj 2 ML***	Yes
90948015002220	5	90948015006320	5	Y	B	*Bone Tissue Allograft (Human) Inj 5 ML***	Yes
90948015002230	5	90948015006330	5	Y	B	*Bone Tissue Allograft (Human) Inj 10 ML***	Yes
90971010004100	5	90979902204100	5	N	A	*Calamine-Zinc Oxide Lotion***	Yes
90971501402072	5	96201050002070	5	N	A	Isopropyl Alcohol 70%	Yes
93000010100900	5	93000010100900	5	C	D	*Charcoal Activated Liq*	Yes
93000010102900	5	93000010102900	5	C	D	*Charcoal Activated Powder*	Yes
95630628250120	5	95630628250110	5	N	B	Ubiquinol Cap 100 MG	Yes
9620105010	4	9620105000	4	A	A	Isopropyl Alcohol	

OLD GPI	OLD REC CD	NEW GPI	NEW REC CD	COMPLETE REPLACE CODE	REASON CODE	NEW GPI NAME	OLD GPI USED IN US†
962010501020	7	962010500020	7	A	A	Isopropyl Alcohol Solution	
96201050102000	5	96201050002000	5	A	B	Isopropyl Alcohol	
96201050102050	5	96201050002050	5	A	A	Isopropyl Alcohol 50%	
96201050102070	5	96201050002070	5	A	A	Isopropyl Alcohol 70%	Yes
97202010006200	5	97202010006410	5	N	B	*Blood Glucose Monitoring Kit w/ Device***	Yes
9720250000	3	9720250000	3	C	D	*Glucose Monitor & Ketone Monitor Combinations***	
97750010006400	5	97750010006200	5	N	B	*Blood Pressure Monitoring - Device***	Yes
99398255012020	5	99398255012020	5	C	D	Nipocalimab-aahu IV Soln 300 MG/1.62ML (185 MG/ML)	
99398255012050	5	99398255012050	5	C	D	Nipocalimab-aahu IV Soln 1200 MG/6.5ML (185 MG/ML)	Yes
9939990215	4	9939990215	4	C	D	Efgartigimod alfa-Hyaluronidase-qvfc	
993999021520	7	993999021520	7	C	D	Efgartigimod alfa-Hyaluronidase-qvfc Solution	
99399902152021	5	99399902152021	5	C	D	Efgartigimod alfa (w/ Hyaluronidase) Inj Soln 180 MG/ML	
99850000000100	5	95606356000100	5	N	A	*Turmeric (Curcuma longa) Cap***	Yes

† 'Yes' in the OLD GPI USED IN U.S. column indicates that the OLD GPI (Record Code Values of '5') is used in a U.S. product that is either active or 48 months inactive from the time that this table was created 07/01/2025). Only Record Code values of '5' will reflect this code. The NEW GPI may or may not be used for a U.S. product. OLD GPI values not coded with a 'Yes' may be used in countries other than the U.S. or are inactive more than 48 months.

In This Section…

Explanation of Values and Symbols

COMPLETE REPLACE CODE

For a complete description of these values, go to the *Electronic File of GPI Changes* section below.

Value	CMPLT-REPLACE Description
Y	**REPLACEMENT: YES,** this is a complete replacement of a GPI (one-to-one replacement)
A	**MERGE: YES,** this is a complete replacement of a GPI (many-to-one replacement)
N	**SPLIT: NO,** this is not a complete GPI replacement (one-to-many replacement)
C	**CHANGE: Change** of GPI or TCS Name only – no change of value
Blank	**NEW RECORD**

REASON CODE

For a complete description of these values, see the *Electronic file of GPI Changes* below.

Reason Code Value	Reason Description
A	Therapeutic Class or Drug Salt Revision (Changes through first 10 positions of GPI)
B	Dosage Form, Route, Strength or Other Change (changes in the last 4 positions of the GPI). Includes new Dosage Forms and Routes-of-Administration.
C	Not Used
D	TCS or GPI Description Change
E	Change due to USP Standards Revision

Electronic File of GPI Changes

A new electronic copy of the GPI changes is available via the Medi-Span website at https://wds.medispan.com. The following is a description of the contents of the Electronic File of GPI Changes.

The Electronic File of GPI Changes is an MS-DOS ASCII file of planned GPI revisions. The effective date of the change is found in the Effective Date field. This file is sorted on the current GPI value and REC-CD. Refer to the following File Layout section below. The GPI field corresponds to the current GPI, and the NEW-GPI field corresponds to the future GPI value (value that becomes effective at the specified effective date).

File Layout

DATAFILE NAME: GPI.CHG

8 ITEMS: STARTING IN POSITION 1

COL	ITEM NAME	WDTH	OPUT	TYP	
1	GPI	14	14	C	
15	REC-CD	1	1	C	(1,2,3,4,5,6,7 or blank)
16	NEW-GPI	14	14	C	
30	NEW-REC-CD	1	1	C	(1,2,3,4,5,6,7 or blank)
31	CMPLT-REPLACE	1	1	C	(Y,A,N,C, or blank)
32	REASON-CD	1	1	C	(A,B,C,D,E)
33	NEW-GPI-NAME	60	60	C	
93	EFF-DATE	8	10	D	(YYYYMMDD)

Note: This Electronic File of GPI changes does not identify the NDC/UPC/HRI/other drug product identifier values impacted by these changes. An Excel spreadsheet of the currently affected U.S. NDC/UPC/HRIs will be available on the Medi-Span website beginning in late July 2025. The complete listing of all affected U.S. NDC/UPC/HRIs, with their new GPIs, will be output with your **September 22, 2025** releases. Weekly, monthly, semi-monthly, and quarterly customers will see these revisions with their **October 1, 2025** releases.

File Layout Descriptions

Following is a description of each item listed in the file layout and in the GPI Changes table:
GPI (GPI) – This is the current Therapeutic Class or GPI value. The field contains 10 characters for Therapeutic Class and 14 characters for GPI.

The GPI value is not unique and may repeat for instances when a GPI goes from one to many. For GPIs that are not complete replacements, the GPI is repeated with each new GPI value that may be used for this split. **You must determine the impact of this change for your application(s).**

The Current GPI field or the NEW-GPI field may be zero-filled depending on the type of change that has

occurred. In addition, the current GPI or NEW-GPI field may only contain ten (10) positions of the GPI for REC-CD or NEW-REC-CD values of '1', '2', '3', '4', '6'. It will contain twelve (12) characters for REC-CD or NEW- REC-CD values of '7' and 14 characters for the GPI REC-CD and NEW-REC-CD values of '5'.

All GPIs affected by these changes are reported in this data element. Your current file may not contain all GPIs found in this field.

Record Code (REC-CD) – This is the current Record Code for the Therapeutic Class or GPI. This field indicates the level of the name. Therapeutic Class records have values of '1', '2', '3', '4', '6', '7'. GPI records have a value of '5'. The Record Code has the following values:

Record Code Value	Record Code Description
1	Drug Group
2	Drug Class
3	Drug Subclass
6	Drug Base Name
4	Drug Name/Drug Name Extension
7	Drug Name and Dosage Form
5	Full GPI NAME
Blank	No corresponding new TC-GPI value

New GPI (NEW-GPI) – This is the new Therapeutic Class or GPI value. The field will contain ten (10) characters for REC-CD or NEW-REC-CD values of: '1', '2', '3', '4', and '6'. It will contain twelve (12) characters for REC-CD or NEW-REC-CD values of '7' and 14 characters for the GPI REC-CD and NEW-REC-CD values of '5'. The New GPI value is not unique and may repeat for instances when a GPI goes from many to one.

New Record Code (NEW-REC-CD) – This is the new Record Code for the Therapeutic Class or GPI. This field indicates the level of the name. Therapeutic Class records have values of '1', '2', '3', '4', '6', '7'. GPI records have a value of '5'. The Record Code has the following values:

Record Code Value	Record Code Description
1	Drug Group
2	Drug Class
3	Drug Subclass
6	Drug Base Name
4	Drug Name/Drug Name Extension
7	Drug Name and Dosage Form
5	Full GPI NAME
Blank	No corresponding new TC-GPI value

Complete Replace Code (CMPLT-REPLACE) – This field is a flag to indicate if all NDC/UPC/HRIs/other drug product identifiers that have the current GPI value are assigned the NEW-GPI. Values are as follows:

CMPLT-REPLACE Value	CMPLT-REPLACE Description
Y	**REPLACEMENT: YES,** this is a complete replacement of a GPI. All NDC/UPC/HRIs/other drug product identifiers with the current GPI and associated classification records are assigned the new GPI values. Current GPI values may be deleted after the effective date of these changes. **(1:1 Replacement - the GPPC will not change for these revisions.)**
A	**MERGE: YES,** this is a complete replacement of a GPI. All NDC/UPC/HRIs/other drug product identifiers with the current GPI and associated classification records are assigned the new GPI values. Current GPI values are deleted after the effective date of these changes. **(Many:1 Replacement - the GPPC may change for these revisions.)**
N	**SPLIT: NO,** this is not a complete GPI replacement. NDC/UPC/HRIs/other drug product identifiers under this GPI may retain the current value or be changed to one of the newly created GPIs identified in the NEW-GPI field. Do not delete the current GPI value after the effective date of these changes – the current GPI value may still be used after these changes. **(1:Many Replacement - NDC/UPC/HRIs/other drug product identifiers that are assigned to a different GPI after these changes will have a corresponding change in the GPPC value.)**
C	**CHANGE: Change** of GPI or TCS Name only – no change of value. Do not delete GPI values associated with this code. **(Output in this file is informational only - the GPPC will not change for these revisions.)**
Blank	**NEW RECORD**: There is no existing record that corresponds to this value. **(0:1 Replacement)**

Reason Code (REASON-CD) - A code indicating the reason for the change is included in position 32. The Reason Code has the following values:

Reason Code Value	Reason Description
A	Therapeutic Class or Drug Salt Revision (Changes through first 10 positions of GPI)
B	Dosage Form, Route, Strength or Other Change (changes in the last 4 positions of the GPI). Includes new Dosage Forms and Routes-of-Administration.
C	Not Used
D	TCS or GPI Description Change
E	Change due to USP Standards Revision

New GPI Name (NEW-GPI-NAME) – This field reflects the name of the new GPI value.

Effective Date (EFF-DATE) – This field reflects the effective date of the GPI Change in YYYYMMDD format.